Anti-E2F4 Monoclonal Antibody

Overview

This product is an anti-E2F4 antibody for target detection and characterization. Key identifiers include host species: Rabbit; Monoclonal; clone AFDF-5; isotype Rabbit IgG; reactivity: Human. Reported application contexts include WB, IHC, ICC, IF, Flow (as provided in the source record). Boster Bio Anti-E2F4 Monoclonal Antibody catalog # M01920. Tested in WB, IHC, ICC/IF, Flow Cytometry applications. This antibody reacts with Human.

Key elements and design rationale

• Target: E2F4 (Inhibitor of nuclear factor kappa-B kinase subunit alpha).
• Antibody format: Monoclonal; clone AFDF-5; isotype Rabbit IgG.
• Host: Rabbit.
• Species reactivity: Human (confirm in your model system with appropriate controls).

This description is intended to help interpret the antibody design and the biological context of the target using the fields provided in the catalog record, alongside general experimental considerations.

Biological background

E2F4 (protein: Lysosome-associated membrane glycoprotein 2 (Lamp2)) is a commonly studied target in molecular and cellular biology. Functional context (as provided): Serine kinase that plays an essential role in the NF- kappa-B signaling pathway which is activated by multiple stimuli such as inflammatory cytokines, bacterial or viral products, DNA damages or other cellular stresses. Acts as part of the canonical IKK complex in the conventional pathway of NF-kappa-B activation and phosphorylates inhibitors of NF-kappa-B on serine residues. These modifications allow polyubiquitination of the inhibitors and subsequent degradation by the proteasome. In turn, free NF-kappa-B is translocated into the nucleus and activates the transcription of hundreds of genes involved in immune response, growth control, or protection against apoptosis. Negatively regulates the pathway by phosphorylating the scaffold protein TAXBP1 and thus promoting the assembly of the A20/TNFAIP3 ubiquitin-editing complex (composed of A20/TNFAIP3, TAX1BP1, and the E3 ligases ITCH and RNF11). Therefore, CHUK plays a key role in the negative feedback of NF-kappa-B canonical signaling to limit inflammatory gene activation. As part of the non-canonical pathway of NF-kappa-B activation, the MAP3K14-activated CHUK/IKKA homodimer phosphorylates NFKB2/p100 associated with RelB, inducing its proteolytic processing to NFKB2/p52 and the formation of NF-kappa- B RelB-p52 complexes. In turn, these complexes regulate genes encoding molecules involved in B-cell survival and lymphoid organogenesis. Participates also in the negative feedback of the non-canonical NF-kappa-B signaling pathway by phosphorylating and destabilizing MAP3K14/NIK. Within the nucleus, phosphorylates CREBBP and consequently increases both its transcriptional and histone acetyltransferase activities. Modulates chromatin accessibility at NF-kappa-B-responsive promoters by phosphorylating histones H3 at 'Ser-10' that are subsequently acetylated at 'Lys-14' by CREBBP. Additionally, phosphorylates the CREBBP-interacting protein NCOA3. . Reported cellular localization context: Cytoplasm . Nucleus . Shuttles between the cytoplasm and the nucleus. Tissue expression notes (as provided): Widely expressed.

Research relevance and current trends

• Research context keywords from the source record include: Domain Families,Epigenetics and Nuclear Signaling,Forkhead Box,Nuclear,Signaling Pathways,Stem Cells,TGF Beta,Transcription.
• Current studies often focus on connecting target abundance/localization to pathway perturbations across models, tissues, and cell states.
• Quantitative and multiplexed assays (e.g., imaging + immunoblot panels) are commonly used to compare phenotypes across conditions and time-courses.

Common research applications

• Western blotting (WB): assess relative target abundance across samples, treatments, or time-points.
• Immunohistochemistry (IHC): evaluate spatial distribution of target-positive staining in tissue architecture.
• Immunofluorescence/ICC (IF/ICC): visualize subcellular localization patterns and cell-to-cell heterogeneity.
• Flow cytometry: quantify target-positive populations and compare shifts in marker distributions.

Workflow ideas (metafield): Validate E2F4 antibody specificity using KO/KD control samples (WB/IF/IHC as appropriate), Detect E2F4 expression by Western blot in cell or tissue lysates, Detect E2F4 in FFPE tissue sections by immunohistochemistry, Localize E2F4 by immunofluorescence/immunocytochemistry in cultured cells, Quantify E2F4-positive cells by flow cytometry in single-cell suspensions

Notes for experimental interpretation

• Consider isoforms and post-translational modifications (PTMs) that may shift apparent molecular weight or epitope accessibility.
• Apparent molecular weight may vary by sample type and processing (observed MW: 85 kDa; calculated MW: 84640 MW).
• Control concepts: include appropriate negative controls (e.g., isotype, KO/KD samples) and orthogonal validation when feasible.

Additional product details (from the source record)

• Molecular weight (observed): 85 kDa
• Cellular localization (provided): Cytoplasm . Nucleus . Shuttles between the cytoplasm and the nucleus.
• Tissue details (provided): Widely expressed.

Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.